These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32384313)

  • 21. Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.
    Nijhawan PK; Katz G; Winter S
    Crit Care Med; 1996 Jun; 24(6):1086-9. PubMed ID: 8681579
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder.
    Storch EA; Larson MJ; Shapira NA; Ward HE; Murphy TK; Geffken GR; Valerio H; Goodman WK
    Depress Anxiety; 2006; 23(7):429-33. PubMed ID: 16841343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
    Levy E; Margolese HC; Sultan S; Chouinard G
    Can J Psychiatry; 2003 Nov; 48(10):709-10. PubMed ID: 14674056
    [No Abstract]   [Full Text] [Related]  

  • 24. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
    J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
    Maina G; Albert U; Salvi V; Bogetto F
    J Clin Psychiatry; 2004 Oct; 65(10):1365-71. PubMed ID: 15491240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
    Potenza MN; Wasylink S; Longhurst JG; Epperson CN; McDougle CJ
    J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
    [No Abstract]   [Full Text] [Related]  

  • 27. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study.
    Scahill L; Riddle MA; King RA; Hardin MT; Rasmusson A; Makuch RW; Leckman JF
    J Child Adolesc Psychopharmacol; 1997; 7(2):75-85. PubMed ID: 9334893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.
    Fontaine R; Chouinard G
    J Clin Psychopharmacol; 1986 Apr; 6(2):98-101. PubMed ID: 3517083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inability to cry during SRI treatment.
    Oleshansky MA; Labbate LA
    J Clin Psychiatry; 1996 Dec; 57(12):593. PubMed ID: 9010124
    [No Abstract]   [Full Text] [Related]  

  • 31. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
    Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Side effects as predictors of drug response in obsessive-compulsive disorder.
    Ackerman DL; Greenland S; Bystritsky A
    J Clin Psychopharmacol; 1999 Oct; 19(5):459-65. PubMed ID: 10505588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoxetine in the treatment of obsessive compulsive disorder.
    Fontaine R; Chouinard G
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):605-8. PubMed ID: 3878975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin syndrome presenting with migrainelike stroke.
    Molaie M
    Headache; 1997 Sep; 37(8):519-21. PubMed ID: 9329236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
    Andrade C
    J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
    [No Abstract]   [Full Text] [Related]  

  • 38. Possible interaction of tramadol and antidepressants.
    Reus VI; Rawitscher L
    Am J Psychiatry; 2000 May; 157(5):839. PubMed ID: 10784494
    [No Abstract]   [Full Text] [Related]  

  • 39. [Obsessive-compulsive symptoms in schizophrenia: remission with anti-obsessive treatment].
    Payá González B; Crespo Facorro B; Sáenz Herrero M; Ayuso Gutiérrez JL
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(3):201-3. PubMed ID: 9717345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.